Multimodal deep learning model for predicting microsatellite instability in colorectal cancer by contrast-enhanced computed tomography and histopathology.
[OBJECTIVES] To develop and validate a multimodal deep learning (DL) model that integrates preoperative contrast-enhanced computed tomography (CECT) and postoperative whole-slide images (WSIs) to pred
- 표본수 (n) 169
- 95% CI 0.732-0.967
- Sensitivity 80.3 %
- Specificity 83.7 %
APA
Tang K, She R, et al. (2025). Multimodal deep learning model for predicting microsatellite instability in colorectal cancer by contrast-enhanced computed tomography and histopathology.. European journal of radiology, 193, 112468. https://doi.org/10.1016/j.ejrad.2025.112468
MLA
Tang K, et al.. "Multimodal deep learning model for predicting microsatellite instability in colorectal cancer by contrast-enhanced computed tomography and histopathology.." European journal of radiology, vol. 193, 2025, pp. 112468.
PMID
41101004
Abstract
[OBJECTIVES] To develop and validate a multimodal deep learning (DL) model that integrates preoperative contrast-enhanced computed tomography (CECT) and postoperative whole-slide images (WSIs) to predict microsatellite instability (MSI) status in colorectal cancer (CRC).
[MATERIALS AND METHODS] This retrospective, multicenter study enrolled 305 CRC patients with paired CECT and WSIs. Patients from Center I and II were allocated to the training (n = 169) and internal validation (n = 85) sets, while those from Center III formed the external test set (n = 51). Pathology-based DL (PathDL) and venous-phase CECT (VPDL) models were constructed using EfficientNet-b0 and ResNet 101 architectures, respectively. A fusion model (F-VP-PathDL, Fusion of venous phase CT and pathology with deep learning) was developed using an adaptive residual network to integrate features from both modalities. Model performance was evaluated using area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, and F1 score.
[RESULTS] The F-VP-PathDL model achieved strong performance on the internal validation set, with an AUC of 0.883 (95 % CI: 0.732-0.967). On the external test set, the model achieved an AUC of 0.905 (95 % CI: 0.831-0.945), outperforming single-modality and alternative fusion models (PathDL: 0.794; VPDL: 0.858; APDL: 0.802; F-AVPDL: 0.813). The model also demonstrated robust accuracy (84.2 %, 95 % CI: 69.1 %-92.8 %), sensitivity (80.3 %, 95 % CI: 28.4 %-98.7 %), specificity (83.7 %, 95% CI: 68.8 %-93.9 %) and F1 score (0.837, 95 % CI: 0.326-0.999) on the external test set.
[CONCLUSIONS] The F-VP-PathDL model demonstrates robust generalizability across centers and offers a clinically scalable tool for MSI prediction in CRC, supporting patient stratification and informing immunotherapy decisions.
[MATERIALS AND METHODS] This retrospective, multicenter study enrolled 305 CRC patients with paired CECT and WSIs. Patients from Center I and II were allocated to the training (n = 169) and internal validation (n = 85) sets, while those from Center III formed the external test set (n = 51). Pathology-based DL (PathDL) and venous-phase CECT (VPDL) models were constructed using EfficientNet-b0 and ResNet 101 architectures, respectively. A fusion model (F-VP-PathDL, Fusion of venous phase CT and pathology with deep learning) was developed using an adaptive residual network to integrate features from both modalities. Model performance was evaluated using area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, and F1 score.
[RESULTS] The F-VP-PathDL model achieved strong performance on the internal validation set, with an AUC of 0.883 (95 % CI: 0.732-0.967). On the external test set, the model achieved an AUC of 0.905 (95 % CI: 0.831-0.945), outperforming single-modality and alternative fusion models (PathDL: 0.794; VPDL: 0.858; APDL: 0.802; F-AVPDL: 0.813). The model also demonstrated robust accuracy (84.2 %, 95 % CI: 69.1 %-92.8 %), sensitivity (80.3 %, 95 % CI: 28.4 %-98.7 %), specificity (83.7 %, 95% CI: 68.8 %-93.9 %) and F1 score (0.837, 95 % CI: 0.326-0.999) on the external test set.
[CONCLUSIONS] The F-VP-PathDL model demonstrates robust generalizability across centers and offers a clinically scalable tool for MSI prediction in CRC, supporting patient stratification and informing immunotherapy decisions.
MeSH Terms
Humans; Deep Learning; Colorectal Neoplasms; Female; Male; Tomography, X-Ray Computed; Microsatellite Instability; Middle Aged; Contrast Media; Retrospective Studies; Aged; Sensitivity and Specificity; Reproducibility of Results; Adult; Aged, 80 and over
같은 제1저자의 인용 많은 논문 (5)
- Mechanistic insights into hypoxia-induced TCF7L2 upregulation and its oncogenic effects on colorectal cancer.
- Accurately Defining the Location and Dimension of the Bony Lid Under the Guidance of Dynamic Navigation: Report on Three Cases.
- Ultrasound-Guided "Cross Injection" Technique for Mouth Corner Lift with Botulinum Toxin Type A.
- Machine learning-driven comprehensive profiling of tumor heterogeneity and sialylation in hepatocellular carcinoma.
- Genetically proxied inhibition of Phosphodiesterase-5 and cancer risks: A drug-target Mendelian randomization analysis.